Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: George Victor who wrote (91329)	9/6/2001 10:25:41 PM
From: Buckey	Respond to of 150070

is this news of note(Applies to: GNLB CHIR) Genelabs Technologies Encouraged by Reports in New England Journal of Medicine Showing Increased Survival When People With HIV are Coinfected With HGV REDWOOD CITY, Calif., Sep 6, 2001 /PRNewswire via COMTEX/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) said that two reports were published today in the New England Journal of Medicine that show patients infected with both the human immunodeficiency virus (HIV) and GB virus C (GBV-C, also known as hepatitis G virus or HGV) had a reduced mortality rate compared to those only infected with HIV. These two studies, published by Xiang, et. al. (Iowa City) and Tillman, et. al. (Hannover, Germany), confirm previous reports suggesting delayed progression of HIV in patients coinfected with GBV-C. Genelabs scientists first discovered HGV, which is transmitted by blood and other bodily fluids, while seeking to identify what was then an unknown hepatitis virus. Patents covering the HGV genome, peptides and their uses have issued to Genelabs. Companies such as Boehringer Mannheim (now Roche Diagnostics), Chiron Corporation and Ortho Diagnostics have licensed diagnostic applications and Genelabs retains all other commercial rights to its discovery of HGV. Jungsuh Kim, Ph.D., Distinguished Research Fellow and leader of the HGV research team at Genelabs Technologies, said, "In collaboration with the Centers for Disease Control and Prevention and the National Institutes of Health, we first identified the hepatitis G virus in a patient and sequenced the entire genome. The HGV molecular characterization was presented at the 16th U.S. - Japan Joint Hepatitis Panel Meeting in January 1995 in Tokyo. To date, despite efforts made in laboratories around the world, HGV infection has not been associated with any significant disease. It is therefore very encouraging that the findings reported today may have implications for the development of new treatments for HIV infection." Since the discovery of the virus, Dr. Kim and her colleagues at Genelabs have collaborated with leading academic researchers and government institutions worldwide, investigating the pathology of infection with HGV. The virus has been reported to be found in approximately 2 percent of all blood donated in the United States, in 15 percent of people infected with hepatitis C, and as high as 40 percent of people infected with HIV. Genelabs Technologies, Inc., is a biopharmaceutical company engaged in the discovery and development of a new class of pharmaceutical products that target DNA. The company is focusing initially on anti-microbial drug discovery, developing compounds that target DNA in bacteria, fungi, viruses and other infectious pathogens. A large number of these compounds have been screened for their activity in cell-based assays and many lead compounds with potent activity in vitro against fungi and bacteria have been identified. Apart from its research, Genelabs is developing Aslera(TM) for systemic lupus erythematosus under a license from Stanford University. NOTE: This press release contains forward-looking statements. These forward-looking statements are based on Genelabs' current expectations and are subject to uncertainties and risks that could cause actual results to differ materially from the statements made. Uncertainties and risks include without limitation the early stage of Genelabs' research programs and uncertainties associated with the optimization of compounds, including whether a compound will advance to pre-clinical testing, clinical trials, or ultimately become a product, and the uncertainty of the timing of any of these; the validity, scope and enforceability of patents related to the company's technologies; whether the results of the company's clinical trials of Aslera(TM) and other supporting information will be sufficient to support the approval of Aslera(TM) by FDA; delays regarding the regulatory approval process including the timing and scope of approval received, if any; uncertainties and risks regarding market acceptance of Aslera(TM) as a treatment for systemic lupus erythematosus (SLE); the company's capital requirements and history of operating losses; and uncertainties and risks regarding the company's ability to consummate strategic or corporate partner transactions on favorable terms or at all. The active ingredient in Aslera(TM) is prasterone, the synthetic equivalent of the androgenic hormone dehydroepiandrosterone (DHEA). Products containing DHEA are currently being marketed by others as dietary supplements. The company has not submitted applications for regulatory review outside the U.S. In addition, neither U.S. nor foreign regulatory authorities have made a determination as to the safety or efficacy of Aslera(TM) for SLE. Please see the information appearing in the company's filings with the Securities and Exchange Commission for more discussion regarding these uncertainties and risks and others associated with the company's research programs, early stage of development and other risks which may affect the company. The company does not undertake any obligation to update these forward-looking statements to reflect events or circumstances after the date of this release.